Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce $0.07 EPS

Equities analysts expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post earnings of $0.07 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.02 and the highest estimate coming in at $0.12. Vanda Pharmaceuticals reported earnings of $0.20 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 65%. The firm is expected to report its next earnings results on Wednesday, November 6th.

On average, analysts expect that Vanda Pharmaceuticals will report full year earnings of $0.30 per share for the current fiscal year, with EPS estimates ranging from $0.27 to $0.33. For the next financial year, analysts expect that the company will post earnings of $0.98 per share, with EPS estimates ranging from $0.20 to $1.75. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.24. The firm had revenue of $59.06 million during the quarter, compared to analysts’ expectations of $54.19 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.15 earnings per share.

A number of research analysts recently issued reports on VNDA shares. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a report on Saturday, October 5th. Stifel Nicolaus reiterated a “hold” rating and issued a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 16th. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, August 1st. Finally, ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $26.71.

In other news, Director Richard W. Dugan sold 15,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.85, for a total value of $222,750.00. Following the sale, the director now owns 50,770 shares of the company’s stock, valued at $753,934.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Timothy Williams sold 2,575 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total transaction of $37,826.75. Following the completion of the sale, the senior vice president now directly owns 57,425 shares in the company, valued at approximately $843,573.25. The disclosure for this sale can be found here. Insiders own 8.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio raised its position in Vanda Pharmaceuticals by 19.5% during the second quarter. Strs Ohio now owns 50,800 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 8,300 shares in the last quarter. Stonepine Capital Management LLC raised its position in Vanda Pharmaceuticals by 6.5% during the second quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock worth $18,908,000 after acquiring an additional 81,655 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Vanda Pharmaceuticals by 4.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 454,759 shares of the biopharmaceutical company’s stock worth $6,408,000 after acquiring an additional 18,447 shares in the last quarter. Northern Trust Corp raised its position in Vanda Pharmaceuticals by 1.0% during the second quarter. Northern Trust Corp now owns 706,666 shares of the biopharmaceutical company’s stock worth $9,957,000 after acquiring an additional 6,938 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in Vanda Pharmaceuticals during the second quarter worth $272,000.

NASDAQ VNDA traded down $0.03 during trading on Friday, reaching $13.66. 334,000 shares of the stock traded hands, compared to its average volume of 772,878. The firm has a market cap of $726.66 million, a price-to-earnings ratio of 28.46 and a beta of 0.32. The stock’s 50-day moving average price is $13.43 and its 200 day moving average price is $14.68. Vanda Pharmaceuticals has a fifty-two week low of $11.83 and a fifty-two week high of $33.44.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.